.jpg)
AstraZeneca offers early look at Datroway-Tagrisso combo in EGFR lung cancer as phase 3 trial rolls on
As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer, the British pharma has rolled out early data from a trial combining the antibody-drug conjugate with its old blockbuster Tagrisso.
As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer, the British pharma has rolled out early data from a trial combining the antibody-drug conjugate with its old blockbuster Tagrisso.
